⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 8, 2024Open Access

Supplementary Figure 5 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

Brandie C. Taylor Xiaopeng Sun Paula I. González-Ericsson Violeta Sánchez Melinda E. Sanders Elizabeth C. Wescott Susan R. Opalenik Ann Hanna Shu-Ting Chou Luc Van Kaer Henry Gómez Claudine Isaacs Tarah J. Ballinger Cesar A. Santa‐Maria Payal D. Shah Elizabeth Claire Dees Brian D. Lehmann Vandana G. Abramson Jennifer A. Pietenpol Justin M. Balko

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Combination anti-PDL1 and anti-NKG2A treatment in genetically modified tumors

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Taylor et al. (2024) studied this question.

synapsesocial.com/papers/68e7b92eb6db64358770f0e8 https://doi.org/10.1158/2159-8290.25191525

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 5 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024
2Supplementary Figure 5 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024
3Supplementary Figure 5 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024
4Supplementary Figure 2 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024
5Supplementary Figure 2 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024